Video & Transcript Research : 'FDA'
Page 10 of 62
TX
Transcript Highlights:
- uh, come up with alternative treatment strategies, and, uh, we will pass those lists on to, uh, The FDA
- Uh, and we continue to work with the USDA, FDA, and EPA, uh, to expand treatment options, uh, for neural
- I can say one thing I did not mention is that we are working closely with the FDA and EPA, as others
- You know, we moved the speed of government that has to be approved by the FDA.
- So there are some outside entities petitioning the FDA to add ivermectin. It's gonna take forever.
FL
Florida 2025 Regular Session
December 9, 2025 - 12:30 PM
Transcript Highlights:
- Fda program of skills, existing dental auxiliary without an added expense to the state.
- The our FDA program uses 2500 hours of experience before anyone can come in.
- We have heard from the FDA, the same arguments for 3 years. Nothing has changed.
- We did the auditor to review for the FDA and the discussion about rescheduling a march last year.
- We were the ones that basically synthesize all the evidence for the FDA on that topic.
MN
Minnesota 2025-2026 Regular Session
House Veterans and Military Affairs Division 4/15/26
Veterans and Military Affairs Division
Transcript Highlights:
- <00:57:41.280>
Just <00:57:41.520>because <00:57:41.920>it is FDA approved, - Just because it is FDA approved, right?
- I think informed consent is hugely important whether it's FDA approved or natural.
- I think informed consent is hugely important whether it's FDA approved or natural.
- hugely important whether it's FDA hugely important whether it's FDA approved<01:02:26.240>
or
Keywords:
veterans, veterans affairs, mental health, behavioral health, rural health, rural areas, access to care, task force, Minnesota Department of Veterans Affairs, general fund appropriation, veteran suicide prevention, PTSD, service members, military families, telehealth, rural psychiatry, high school diploma, armed forces, education policy, military service
OK
Oklahoma 2026 Regular Session
Senate Legislative Session Mar 10th, 2026 at 01:30 pm
Oklahoma Senate Floor Meeting
Transcript Highlights:
- Our program FDA found that our authority was limited to only cows and goat milk and requested this change
- in our state law to match federal delegated authority that ODE has been granted from FDA.
- President, since it is my understanding that the FDA is wanting to bring all these definitions under
- This was a request bill that was brought to me by the Department of Agriculture to get us in line With FDA
- From the USDA and the FDA on our ag industry in the state.
Bills:
HB1427, SB1403, SB1448, SB1489, SB1546, SB1557, SB1614, SB1377, SB1990, SB1439, SB1630, SB1632, SB1696, SB1796, SB1824, SB1362, SB1849, SB2066, SB2071, SB2104, SB933, SB1633, SB1224, SB1246, SB1280, SB1303, SB1346
Keywords:
tax credit, clean-burning fuel, hydrogen fuel cells, compressed natural gas, liquefied petroleum gas, environmental impact, vehicle modification, renewable energy, job incentives, tax rebates, Oklahoma Quality Jobs Program, employment growth, wage requirements, Oklahoma Consumer Protection Act, consumer protection, unfair trade practices, deceptive practices, exemptions, statutory exemptions, Corporation Commission
WV
West Virginia 2026 Regular Session
WV Senate Mar 14th, 2026 at 04:37 pm
Transcript Highlights:
- and passed Senate Bill 906, permitting lawful prescription of crystalline polymorph psilocybin under FDA
- Senate Bill 906, permitting lawful prescription of crystalline polymorph psilocybin under FDA recommendations
- Food and Drug Administration approval and is rescheduled by the FDA as being lawful, prescribed, distributed
- Food and Drug Administration approval and is rescheduled by the FDA as being lawful, prescribed, distributed
Summary:
The Senate first considered confirmations from Senate Executive Message No. 4. On a 33-0 vote, it confirmed all nominees except number 54, then separately confirmed nominee 54 on a 30-3 vote. The special order of business was then closed.
The chamber then took up a series of House-amended bills and generally concurred in the amendments before passing each bill. These included SB 723 on law enforcement cooperation with bordering states; SB 947 on birth certificate copies for homeless minors; SB 392 on personal income tax reduction; SB 54 on criminal penalties for abuse or neglect of incapacitated adults; SB 228 on technology in child abuse and neglect investigations, including a three-county caseworker aid pilot; SB 231 on value-based payment requirements; SB 402, the Workforce Readiness Opportunity Act, with House removal of tax credits and other provisions while retaining micro-credential programs; SB 553 on transfer of contractor licenses to qualifying immediate family members; SB 575 on refusal review hearings; SB 686, the Coal Tenancy Modernization and Miners' Protection Act; SB 906 on lawful prescription of crystalline polymorph psilocybin under FDA recommendations; and SB 1226 on penalties for disturbing religious worship. Most final passage votes were unanimous or near-unanimous, and several bills were made effective from passage or given a specific effective date.
Later, the Senate concurred in House amendments to SB 63, the Creating Sustaining Opportunities for Academics and Rural Schools Act, after discussion noting the House removed county charter school language and changed the effective date. The bill passed 32-2 and was made effective from passage. The Senate also concurred in amendments to SB 502, the Women's Collegiate Sports Protection Act, and SB 153, creating the Unemployment Automation and Administration Fund; SB 502 was set to take effect July 1, 2026, and SB 153 was also made effective July 1, 2026. Finally, the Senate reconsidered and again passed SB 392 by a 32-2 vote. The session ended with several introductions, announcements, and a recess until 5:30.
US
US Federal 2025-2026 Regular Session
Hearings to examine the nomination of Robert F. Kennedy, Jr., of California, to be Secretary of Health and Human Services. Jan 30th, 2025 at 09:00 am
Health, Education, Labor, and Pensions Committee
Transcript Highlights:
- Do you promise that FDA will not deprioritize our delay review and our approval of new vaccines and that
- So let me read again: promise that the FDA will not deprioritize our delay review and our approval of
- Are you aware of the FDA post-approval monitoring? I'm aware of only two systems.
- We have 10,000 ingredients in our food in this country because the FDA employs a standard called the
- We are attracting the most talented group of people who work in NIH, CDC, and FDA in modern history.
MN
Minnesota 2025 1st Special Session
Committee on Agriculture, Veterans, Broadband and Rural Development - 04/21/25
Agriculture, Veterans, Broadband, and Rural Development
Transcript Highlights:
- In 2016, the FDA received a citizen petition to ban phthalates in food contact materials.
- The FDA is now seeking...
- In 2016 the FDA received a children.
- So this bill could actually provide valuable information for the FDA to use in their review.
- In May of 2022, the FDA removed 23 phthalates from the use in food packaging.
MN
Minnesota 2025-2026 Regular Session
House Health Finance and Policy Committee 2/25/26 - Part 1
Health Finance and Policy
Transcript Highlights:
- House File 1807 ensures Minnesota's Medicaid program does not favor opioids or FDA-approved non-opioid
- There are a number of FDA-approved nonopioid pain therapies that are currently available on the market
- And so our drug formulary committee would consider that information from the FDA.
- <00:38:11.599>
So, <00:38:11.760>the information from the FDA. - So, the information from the FDA.
Keywords:
hospital moratorium, hospital construction, bed capacity, hospital expansion, health care facilities, hospital licensing, safety-net hospital, level I trauma center, Ramsey County, Minnesota health law, hospital beds, new hospital exception, certificate of need, inpatient capacity, emergency care, trauma services, health system regulation, state moratorium, hospital modernization, health infrastructure
CA
California 2025-2026 Regular Session
Assembly Business and Professions Committee Jun 23rd, 2026
Business and Professions
Transcript Highlights:
- These products are not FDA approved and have raised alarms due to an increase in poison control calls
- nitrous oxide can cause long-term neurologic effects paralysis and even death these products are not FDA
- It aligns California with FDA clinical evolution and Medicare policy, allowing for the automatic substitution
- It aligns California with FDA clinical evolution and Medicare policy, allowing for the automatic substitution
- SB 1094 allows pharmacists to substitute FDA-approved biosimilars unless the prescriber indicates otherwise
AZ
Transcript Highlights:
- to make sure that you have a license and that you're going through the proper controls of what the FDA
- So I think the FDA probably would already have that."
- "Through the proper controls of what the FDA has.
- So I think the FDA probably would already have that outline, and obviously that's a federal mandate and
AZ
Transcript Highlights:
- And this language comes straight from their FDA-authorized letter.
- So there is, this is the only company; there's one other company that's FDA-approved. Yes.
- It was approved by the FDA in 2021, so it's been available for the past four years.
- And now the very first one has been FDA approved.
- "At this time, this FDA-approved?
Bills:
HB2176, HB2333, HB2435, HB2447, HB2617, HB2683, HB2686, HB2725, HB2726, HB2906, HB2953, HB2958
Keywords:
health care, licensure, complaints, investigation, safety, patient care, regulatory compliance, prosthetics, orthotics, health insurance, Medicare, medical necessity, disability rights, coverage, reimbursement, internationally trained physicians, medical board, clinical training, provisional license, healthcare workforce
Summary:
The committee heard and acted on several health care bills. HB 2726 would require Access contractors to cover diagnosis and treatment of mild obstructive sleep apnea, including a new prescription tongue-stimulation device; supporters said it offers an effective, less burdensome alternative to CPAP and could improve adherence and outcomes, while Access was neutral and raised concerns about cost and bypassing its normal clinical review. The committee adopted the Bliss amendment and then approved HB 2726 as amended on an 8-4 due-pass vote.
HB 2435 would create a pathway for internationally trained physicians to receive a provisional Arizona medical license, with a later amendment adding a four-year supervised rural practice requirement and automatic conversion to a full license if criteria are met. Supporters argued it would help address severe physician shortages in rural and underserved areas, especially for cardiology and other specialties, and several doctors testified about their experience and the need for more access. Opponents, including the Arizona Medical Board, said the state already has a case-by-case licensure process for foreign-trained physicians and warned the bill could weaken safeguards and allow insufficiently vetted applicants. After adopting the amendment, the committee approved HB 2435 as amended on a due-pass recommendation.
HB 2958 would require Access to cover comprehensive dental care for pregnant women age 21 and older, with a $500,000 pilot program and reporting requirements. The sponsor and public health advocates said preventive dental care during pregnancy can reduce infections and improve maternal and infant outcomes, and the bill drew broad support from health and advocacy groups. The committee passed HB 2958 on an 11-1 due-pass vote.
The committee also approved HB 2176, which changes criteria and timelines for health care institution licensing complaints and informal dispute resolution, with supporters saying it would improve transparency and predictability for hospitals while preserving enforcement authority. Finally, the committee heard HB 2447, which would bar insurers from paying certified registered nurse anesthetists less than physicians for the same anesthesia service; opponents argued it would interfere with contract negotiations and raise costs, while supporters said insurer reimbursement cuts are harming rural access and shifting costs to hospitals. The transcript ends during testimony on HB 2447, before any committee vote on that bill.
TX
Texas 89th Regular
Senate Committee on Health and Human Services May 20th, 2025
Health & Human Services
Transcript Highlights:
- Medical contraindications, emergency use authorization, or full FDA approval of the vaccine.
- Senator Hancock, you are aware of the changes that the FDA has made regarding COVID-19.
- So I'm looking at the stuff that came out from the FDA. It looks like today.
- The FDA is making changes to the requirements as they move forward.
- I think what the CDC and the FDA are going to say is regarding healthy patients.
Bills:
HB163, HB216, HB721, HB2035, HB2038, HB3057, HB3153, HB3233, HB3595, HB3801, HB3812, HB4076, HB4129, HB4377, HB4535, HB4666, HB4730, HB4743, HB4903, HB5149, HB5155, HB1534, HB163, HB216
Keywords:
epinephrine, healthcare, emergency response, administration, medical policy, health care, itemized billing, patient rights, provider regulations, Texas Health and Safety Code, cost disclosure, insurance, benefit plan, administrators, chemical dependency, treatment facilities, minor admissions, parental notice, mental health, medical licensing
HI
Hawaii 2026 Regular Session
HHS-AEN-EIG, HHS, HHS Public Hearings 02-02-2026
Health and Human Services
Transcript Highlights:
- proposal limits access to legal FDA proposal limits access to legal FDA regulated<00:35:11.040><
- <00:36:14.960>
FDA regulated extensively by the FDA. - FDA regulated extensively by the FDA.
- is unsafe, the FDA has more than<00:36:30.640>
enough <00:36:30.880>power <00:36:31.200 - But thankfully the<00:36:51.839>
FDA <00:36:52.320>has <00:36:52.560>never <00:36
Summary:
The joint HHS, Agriculture, Environment, Energy, and Intergovernmental Affairs hearing focused first on SB 2262, a pollution and illegal dumping measure. The Department of Health said it stood on its written testimony, and public testimony included support from CARES with suggested amendments to involve the counties in standardized response planning and to address pollution caused by individuals. Members questioned the bill’s fines, where they would go, and how the department would handle carcasses and illegal dumping enforcement. DOH said administrative fines go to the general fund, criminal fines are collected by the Attorney General, carcasses are generally buried by the landowner under existing rules, and DOH mainly regulates solid waste and coordinates with counties and other agencies when violations arise.
After discussion, the chair recommended SB 2262 be passed with substantial amendments. The proposed amendments would add DLNR to the task force, deposit all fines into a special fund to support enforcement, allow fines below $5,000 for littering and higher fines for excessive or chronic illegal dumping, and include a January 30, 2050 effective date. The committee adopted the recommendation, with members voting aye.
The hearing then moved to the HHS calendar. On SB 2087, relating to health insurance, agencies including DHS, DCCA, the Attorney General, and Labor stood on written testimony, while several advocacy and medical groups testified in support. One Medicaid recipient opposed the bill, arguing the coverage should be immediate rather than phased in over three years. Angela Melody Young supported the bill but urged amendments to prioritize people with disabilities, kupuna, and mothers. Members questioned whether the rural health transformation program could support the bill’s deductible structure; the Department of Human Services said it was unlikely CMS would allow that level of coverage, though rural funds might help in other ways. The committee then moved on to SB 2089, which would expand services eligible for Medicaid prospective payment system reimbursement, hearing support from OHA, DHS, and others, along with testimony about mental health access and training. The transcript also began SB 2106, relating to health and eating disorder prevention, with a student testifying in support and citing youth eating disorder harms, but the discussion was cut off before any action on that bill.
AZ
Transcript Highlights:
- to make sure that you have a license and that you're going through the proper controls of what the FDA
- So I think the FDA probably would already have that."
- "Through the proper controls of what the FDA has.
- So I think the FDA probably would already have that outline, and obviously that's a federal mandate and
Summary:
The Senate opened with prayer, the pledge, attendance, and routine journal and communication actions, including a temporary committee replacement appointment and confirmation of Todd D. Haney to the State Board of Education. The chamber then moved into the Committee of the Whole to consider House Bill 4001, which concerns vaping/nicotine product regulation. Members debated a committee amendment and a floor amendment offered by Senator Bolick; supporters described the bill as a first step toward regulating harmful products and keeping them away from children, while opponents argued it was too weak, lacked retail licensing and enforcement, and did not adequately protect public health. The Committee of the Whole adopted the amendments and recommended the bill do pass, and the full Senate later passed HB 4001 on a 24-0-1 vote after additional debate on the same public health and enforcement concerns.
The Senate then took up several other measures on final reading. House Bills 2720, 2078, 2501, 2686, and 2574 all passed, with votes ranging from 17-7 to 26-0. The chamber also concurred in House amendments to several Senate bills, including SB 1067, SB 1172, SB 1232, SB 1214, and SB 1478. During debate on HB 2078 and other bills, members used points of personal privilege to recognize staff and explain votes, but no additional amendments were adopted on those measures.
On final readings, SB 1566, dealing with residential construction and delay enforcement, passed 17-9 despite concerns that its definition of malicious delay was too broad and could invite litigation. SB 1067, SB 1172, SB 1232, SB 1426, and SB 1478 also passed, with some members speaking in support of homeowner protections, administrative changes, or liquor policy updates, while others opposed the liquor bill and raised public health concerns about alcohol access in border communities. The Senate concluded by announcing party caucuses and adjourning until June 1, 2026.
HI
Hawaii 2026 Regular Session
HLT/HSH Joint Public Hearing - Wed Feb 4, 2026 @ 9:00 AM HST
Transcript Highlights:
- Uh, first up we have um from the FDA.
- The FDA has sale in the United States.
- list of these authorized FDA products. list of these authorized FDA products.
- <01:56:11.679>
And a change to this list by the FDA. - And a change to this list by the FDA.
Summary:
The joint hearing opened with House Bill 1969, which would provide state funding for colorectal cancer screenings for uninsured and underinsured residents. The Department of Human Services said it supports the goal of early screening but would need new administrative capacity, including a program manager and claim pre-screening, to run the program. The Department of Health supported the measure and cited low screening rates in Hawaii, noting an educational campaign to encourage screening. The Insurance Division raised concerns about reliance on federal FAQs, warning that guidance can change and may create state cost exposure. Supporters including the American Cancer Society Cancer Action Network and the Hawaii Medical Association argued the bill would close a preventive-care gap, reduce late-stage diagnoses, and save long-term costs; the committee also discussed implementation costs, estimated by DHS at roughly $1.4 million to $2 million annually plus administrative expenses, and a 6-month to 1-year timeline to establish the program.
The committee then took up House Bill 1965, which would require health carriers to spend at least 6% of total medical expenditures on primary care providers. The Insurance Division said several provisions raise technical and legal concerns, including the premium freeze, the medical loss ratio language, the lack of an existing external review process for downcoding claims, and a new mandate for medically necessary inter-island transportation that could trigger an ACA defrayal. The Department of Human Services supported the intent but suggested broader language to include primary care supports and services, and noted that QUEST integration plans already invested at least 9% of total medical expenditures in primary care in 2024, with additional spending on supports and low-value care reductions. State health planning officials strongly supported the bill as an investment in primary care, saying it could improve outcomes and lower long-term costs, though they acknowledged a possible temporary premium increase during the transition.
Testimony in support emphasized Hawaii’s physician shortage, especially on Maui, the Big Island, and other neighbor islands, and warned that clinics are under financial strain and may close without higher primary care reimbursement. The Hawaii Healthcare Task Force, AARP Hawaii, and other supporters said the bill would help retain providers, improve access for Medicare and Medicaid patients, and prevent downstream costs from emergency room use and avoidable hospitalizations. No votes or final committee action were taken in the portion of the hearing provided.
HI
Hawaii 2026 Regular Session
HHS, HHS DEFER Public Hearings 02-18-2026
Transcript Highlights:
- respond adequately to current FDA respond adequately to current FDA approved<00:04:28.560>
PTSD - Congress three times on suicide prevention and granting breakthrough therapies by the FDA.
- This opportunity for Hawaii to the FDA.
- , because there's also requirements about allowing FDA-approved drug use in hospitals.
- Thank you. >> And the FDA does work.
Summary:
The committee heard testimony on SB 3025, relating to medical debt, with multiple organizations and individuals, including the Office of Wellness and Resilience, Healthcare Association of Hawaii, Queens Health Systems, the American Cancer Society Cancer Action Network, Aloha Care, Hawaii Health and Harm Reduction, Hawaii Data Collaborative, and Hawaii Appleseed, all speaking in support. No opposition was heard, and the member present had no questions.
The committee then took up SB 3199, which would establish a mental health emerging therapies task force. Testimony was overwhelmingly in support, with speakers including veterans, clinicians, researchers, and advocacy groups describing personal experiences with PTSD, depression, traumatic brain injury, and treatment-resistant conditions, and arguing that Hawaii should prepare for regulated access to emerging therapies such as MDMA, psilocybin, ketamine, and ibogaine. The Department of Health and some medical organizations provided comments, and one opposition witness was called but not present. The chair noted broad support, especially from veterans, and no vote was taken during the excerpt.
The final measure discussed was SB 3324, relating to Medicaid. The Department of Human Services, Department of Health, Hawaii State Council on Developmental Disabilities, Hawaii Disability Rights Center, Aloha Care, and numerous care-provider and aging/disability organizations testified in support, while one witness was in opposition and several others offered comments. The discussion then moved to SB 2563, relating to homelessness, where the Department of the Attorney General offered comments on specific sections and recommended adopting suggested amendments if the bill proceeds. Additional testimony on SB 2563 began with support from several individuals, including Shelby Pikachu, who emphasized the severity of homelessness and related social problems in the community.
MA
Massachusetts 2025-2026 Regular Session
Joint Committee on Children, Families and Persons with Disabilities Jun 21st, 2026 at 01:00 pm
Joint Committee on Children, Families and Persons with Disabilities
Transcript Highlights:
- The FDA has tried multiple times to ban the electric shock devices as used at the Judge Rotenberg Center
- So the Congress gave the FDA the power that it needed to ban the device.
- Level 3 aversive, which is a number set by the FDA for the most risky and harmful potential devices.
- aversives have been denounced by psychology experts, disability advocates, the United Nations, the FDA
- The FDA warns the public.
Summary:
The committee held a hybrid hearing on a range of bills affecting children, families, disability rights, homelessness, and social services. Early testimony focused on H.215, which would support children experiencing homelessness by speeding access to child care vouchers and early intervention screenings. Boston officials, Horizons for Homeless Children, Head Start, pediatric and early education advocates, and families described delays in child care and early intervention, the developmental risks of homelessness, and the need for automatic referrals and faster access to services. Testimony also supported H.216, which would improve emergency housing assistance by restoring presumptive eligibility, reducing documentation barriers, extending shelter stays from six to nine months, and creating an ombudsperson; providers and legal advocates said current rules leave families sleeping in cars or outside and create unnecessary administrative hurdles.
The committee also heard strong support for H.210, which would repeal the “Learn Fair” school attendance sanction that cuts cash assistance to families when children miss school. Advocates from legal aid, education, and anti-poverty organizations argued the policy is punitive, burdensome, and ineffective, disproportionately affecting low-income, disabled, and Hispanic/Latino families. Several speakers said chronic absenteeism should be addressed through supports such as family outreach, wraparound services, and school engagement rather than benefit cuts. Legislators and school officials from Salem also testified that their districts reduced absenteeism through supportive strategies, not sanctions.
Additional testimony addressed children’s vision bills H.202 and H.166, with optometrists and researchers urging better screening, data systems, and treatment access to close achievement gaps caused by untreated vision problems. Senator Lovely also presented S.2714, proposing a study of discrimination in public accommodations for people with service animals. Later, testimony on H.279 supported changing social work licensure rules to remove exam requirements that speakers said disproportionately exclude multilingual candidates and candidates of color. The hearing also included testimony on bills related to the Judge Rotenberg Center and electric shock devices, with disability rights advocates opposing continued use of the devices and urging the committee to reject licensing or authorization for them. No votes or committee actions were taken during the hearing.
TX
Transcript Highlights:
- The FDA changed its requirements this week.
- You are aware of the changes that the FDA has made regarding the COVID vaccine? What specifically?
- You are aware of the changes that the FDA has made regarding the COVID vaccine? What specifically?
- So I'm looking at the stuff that came out from the FDA. It looks like today.
- I think what the CDC and the FDA are going to say is healthy patients.
Bills:
HB163, HB216, HB721, HB2035, HB2038, HB3057, HB3153, HB3233, HB3595, HB3801, HB3812, HB4076, HB4129, HB4377, HB4535, HB4666, HB4730, HB4743, HB4903, HB5149, HB5155, HB1534
Keywords:
epinephrine, healthcare, emergency response, administration, medical policy, health care, itemized billing, patient rights, provider regulations, Texas Health and Safety Code, cost disclosure, insurance, benefit plan, administrators, chemical dependency, treatment facilities, minor admissions, parental notice, mental health, medical licensing
Summary:
The committee met without a quorum at first, then established a quorum with five members present. Members heard and left pending several House bills, including HB 4743 on allowing hospitals to license mobile stroke units under a hospital license, HB 4129 on earlier DFPS enforcement tools for single-source continuum contractors in community-based foster care, HB 4903 creating a Quad Agency Child Care Initiative to coordinate child care regulations across state agencies, HB 3812 revising the gold card/prior authorization process for physicians, HB 4535 requiring written informed consent before COVID-19 vaccination and a standardized state information sheet, and HB 4666 reducing the frequency of some HHSC reports to the legislature. The chair also noted HB 35 would be voted on later after a subcommittee back was received, and that a large number of bills would be heard the next day.
Most of the testimony focused on HB 4535 and HB 4730. On HB 4535, supporters argued the bill would strengthen informed consent for COVID vaccination by requiring written consent and clearer state-level information about risks, manufacturer liability protections, and adverse-event reporting; opponents, including a pediatrician and medical groups, said existing federal and state informed-consent materials already cover these topics and warned the bill could create duplicative paperwork and penalties. On HB 3812, the Texas Medical Association supported changes that would extend the gold-card evaluation period to one year, raise transparency, and make prior authorization exemptions easier to administer, while health plans said they were neutral and viewed the bill as a balance between reducing burden and preventing fraud or unsafe care.
HB 4730 drew extensive testimony from adoption professionals, birth mothers, adoptive parents, and child welfare advocates. The bill would require DFPS to create a relinquishment form, train child-placing agency staff, and extend the minimum waiting period for voluntary relinquishment from 48 hours to seven days. Supporters of the current law argued the 48-hour period aligns with hospital discharge, allows informed decisions, and helps birth parents and adoptive families begin healing and bonding without pushing children into foster care or creating legal and Medicaid complications. The author said the bill would be revised and that the seven-day provision was a work in progress. No votes were taken on the bills during the meeting; each bill was left pending after public testimony closed.
FL
Florida 2026 4th Special Session
February 5, 2026 - 09:30 AM
Transcript Highlights:
- And probably because the the FDA has not approved at this time, this product to actually help folks quit
- And and going to the FDA, you know, FDA at AB getting agree with a treaty, menopausal women and for many
- And and in truth be told, the FDA has released authorization of this product to be in a harm modified
CA
California 2025-2026 Regular Session
Assembly Environmental Safety and Toxic Materials Committee Jul 1st, 2025
Transcript Highlights:
- Manufacturers also share that commitment and already, as mentioned in the analysis, operate under FDA
- The FDA currently regulates and approves menstrual products for the market as medical devices for safety
- In January of this year, the FDA conducted an independent review, which concluded that there are no safety
- The FDA continues to recommend FDA-cleared tampons as a safe option for use as a menstrual product.
Summary:
The Assembly Environmental Safety and Toxic Materials Committee heard three bills after beginning without a quorum and later establishing one. SB 328 would cap DTSC hazardous waste generation and handling fees for infill housing and master development projects and set response timelines for cleanup reviews. Supporters said the current fee structure has made some housing and remediation projects infeasible, while opponents warned that capping fees for one sector could shift costs to other hazardous waste generators. The committee discussed the need for broader DTSC fee reform, and SB 328 was approved on a 7-0 vote and sent to the Committee on Revenue and Taxation.
SB 754 would require manufacturers of disposable menstrual products to test for and disclose concentrations of certain contaminants, with DTSC able to verify results and publish them. Supporters framed the bill as a transparency and public health measure, citing recent studies finding toxic metals in tampons and emphasizing consumer right-to-know. Opponents, including manufacturers and hygiene product groups, argued the bill adds duplicative testing, vague requirements, and public disclosure that could be misinterpreted, and urged amendments. The committee members generally supported the goal of transparency, and the bill passed 5-2 with not voting members, moving to Appropriations.
SB 466 would provide temporary legal protections for public water systems that are complying with approved chromium-6 compliance plans while they work toward the new drinking water standard. Supporters from Los Banos, Coachella Valley Water District, and other water agencies said the measure would help avoid costly litigation during a lengthy and expensive compliance period, especially for systems dealing with naturally occurring chromium-6. Committee members raised concerns about limiting recourse for harmed individuals and discussed possible alternative language, but the author said the bill would not affect state enforcement authority. SB 466 passed 7-0 and was sent to the Committee on Judiciary. The committee also adopted a consent calendar of additional measures by voice vote.